Novo Nordisk (NYSE: NVO) details DKK 3.4B B-share repurchases

Rhea-AI Filing Summary

Novo Nordisk A/S reports progress on its ongoing share repurchase programme. As part of a broader plan to buy back up to DKK 15 billion of shares over 12 months beginning 4 February 2026, the company is running a sub-programme to repurchase B shares for up to DKK 3.8 billion between 4 February 2026 and 4 May 2026.

As of 24 April 2026, Novo Nordisk has repurchased 13,407,992 B shares at an average price of DKK 256.48, for a total value of DKK 3,438,931,195. Following these purchases, Novo Nordisk holds 30,797,791 B shares as treasury shares, equal to 0.7% of its total share capital of 4,465,000,000 A and B shares, including treasury shares.

Key Figures

Total buyback programme size: DKK 15 billion Current sub-programme cap: DKK 3.8 billion B shares repurchased: 13,407,992 B shares +5 more

8 metrics

Total buyback programme size DKK 15 billion Planned B share repurchases over 12 months from 4 Feb 2026

Current sub-programme cap DKK 3.8 billion B share repurchases from 4 Feb 2026 to 4 May 2026

B shares repurchased 13,407,992 B shares Total repurchased from 4 Feb 2026 to 24 Apr 2026

Repurchase transaction value DKK 3,438,931,195 Value of 13,407,992 B shares bought by 24 Apr 2026

Average repurchase price DKK 256.48 per B share Average price paid from 4 Feb 2026 to 24 Apr 2026

Treasury B shares 30,797,791 B shares Held as treasury shares after reported transactions

Treasury share percentage 0.7% of share capital Portion of total A and B share capital held in treasury

Total shares outstanding 4,465,000,000 shares Total A and B shares including treasury shares

Key Terms

share repurchase programme, Safe Harbour Rules, treasury shares, ADR, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

Safe Harbour Rules regulatory

"in accordance with ... the Commission Delegated Regulation (EU) 2016/1052 ... (the "Safe Harbour Rules")"

treasury shares financial

"Novo Nordisk owns a total of 30,797,791 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

ADR financial

"Its ADRs are listed on the New York Stock Exchange (NVO)."

An American Depositary Receipt (ADR) is a financial certificate that lets investors buy shares of a foreign company through U.S. stock markets, similar to buying a local wrapper that represents the underlying foreign shares. ADRs matter because they make investing in overseas companies easier and more liquid by trading in U.S. dollars and under U.S. market rules, while still carrying currency, regulatory, and country-specific risks that can affect share value.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 04/27/2026 - 07:21 AM Learn about SEC filing dates

FAQ

What share repurchase plan did Novo Nordisk (NVO) outline in this 6-K?

Novo Nordisk described a share repurchase programme of up to DKK 15 billion over 12 months beginning 4 February 2026. Within this, a sub-programme targets up to DKK 3.8 billion of B share buybacks between 4 February 2026 and 4 May 2026.

How many Novo Nordisk (NVO) B shares have been repurchased so far in 2026?

As of 24 April 2026, Novo Nordisk has repurchased 13,407,992 B shares since 4 February 2026. These shares were bought at an average price of DKK 256.48, corresponding to a total transaction value of DKK 3,438,931,195 under the current programme.

What portion of Novo Nordisk (NVO) share capital is held as treasury shares?

After the reported buybacks, Novo Nordisk holds 30,797,791 B shares of DKK 0.10 as treasury shares. This position corresponds to 0.7% of the company’s total share capital of 4,465,000,000 A and B shares, including treasury shares.

Over what period will Novo Nordisk (NVO) execute its DKK 15 billion buyback?

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12‑month period beginning 4 February 2026. The current sub-programme, capped at DKK 3.8 billion, runs from 4 February 2026 to 4 May 2026.

On which exchanges are Novo Nordisk (NVO) shares listed?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under the symbol Novo-B. Its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the ticker NVO, giving investors access in both European and U.S. markets.

Where can investors find detailed daily transactions for Novo Nordisk’s buyback?

The company states that detailed information for each transaction under the share repurchase programme is published on novonordisk.com. Investors can review daily numbers of B shares repurchased, average purchase prices, and transaction values for additional transparency.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

April 27, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 20 April 2026, the following transactions have been made:

		Number of B shares		Average purchase price		Transaction value, DKK
Accumulated, last announcement		12,257,992				3,148,710,807
20 April 2026		230,000		255.92		58,861,892
21 April 2026		230,000		255.95		58,868,391
22 April 2026		230,000		249.65		57,420,415
23 April 2026		230,000		249.19		57,313,744
24 April 2026		230,000		251.11		57,755,946
Accumulated under the programme		13,407,992				3,438,931,195

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 30,797,791 B shares of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 24 April 2026, Novo Nordisk has since 4 February 2026 repurchased a total 13,407,992 B shares at an average share price of DKK 256.48 per B share equal to a transaction value of DKK 3,438,931,195.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:		Liz Skrbkova (US)
Ambre James-Brown		+1 609 917 0632
+45 3079 9289		lzsk@novonordisk.com
globalmedia@novonordisk.com
Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
nvno@novonordisk.com		jrde@novonordisk.com
Max Ung		Sina Meyer
+45 3077 6414		+45 3079 6656
mxun@novonordisk.com		azey@novonordisk.com
Alex Bruce		Christoffer Sho Togo Tullin
+45 34 44 26 13		+45 3079 1471
axeu@novonordisk.com		cftu@novonordisk.com
Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
fptr@novonordisk.com		mbbz@novonordisk.com
Company announcement No 28

Page 2 of 2

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 28 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 27, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer